Sunday , October 22 2017
Home / Managing Editor, Diabetes in Control (page 6)

Managing Editor, Diabetes in Control

Managing Editor, Diabetes in Control

Did You Know: What Are the SGLT-2 Inhibitor Trade-offs?

george_bakris

The overall profile of sodium-glucose cotransporter 2 inhibitors suggests they are a reliable, second-line therapy choice for adults with type 2 diabetes. However, the class is associated with possible side effects that should be carefully considered, according to a Dr. George L. Bakris, MD, director of the ASH Comprehensive Hypertension Center at the University of Chicago Medicine at a recent presentation at the Cardiometabolic Health Congress. Dr. Bakris stated that they definitely are preferred second-line agents, absolutely over sulfonylureas, and probably over thiazolidinediones and some other agents as well.

Read More »